Mitoxantrone Sandoz (Mitoxantrone)

The drug intercalates into DNA and blocks topoisomerase II activity, preventing the resealing of DNA strands during replication. This leads to accumulation of DNA breaks, triggering programmed cell death (apoptosis) in rapidly dividing cancer cells.

The prescribed dose of Mitoxantrone Sandoz is determined by the treating physician based on the specific indication, patient weight, renal and hepatic function, and prior treatment history. Dosing regimens are individualized and should follow the prescriber’s instructions.

Mitoxantrone is classified as pregnancy category unknown and is generally avoided in pregnant or nursing women because of potential fetal toxicity and secretion in breast milk. Effective contraception is recommended for women of child‑bearing potential during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Mitoxantrone belongs to the anthracenedone class, offering a distinct toxicity profile compared with anthracyclines such as doxorubicin. While both inhibit topoisomerase II, Mitoxantrone is associated with a lower incidence of acute cardiotoxicity but carries a higher risk of secondary leukemia, requiring careful risk‑benefit assessment.

Mitoxantrone Sandoz should be stored at 2‑8 °C in a refrigerator, protected from light. The vial must not be frozen or shaken, and it should remain in its original packaging until ready for use to maintain stability.

The medication is supplied as an injectable solution for intravenous infusion. It is typically diluted in a compatible carrier fluid and administered over a prescribed period by a trained healthcare professional in a clinical setting, with monitoring for infusion‑related reactions.

Serious risks include cardiotoxicity leading to reduced heart function, the development of secondary acute leukemia, severe infections due to profound neutropenia, hepatic injury, and pulmonary toxicity. Patients should be monitored regularly for these complications throughout treatment.

Patients with pre‑existing severe cardiac disease, uncontrolled infections, known hypersensitivity to Mitoxantrone or its excipients, and those who are pregnant or breastfeeding should not receive the drug. Additionally, individuals receiving other cardiotoxic agents should be evaluated carefully before use.